乐普生物-B2024年业绩亮眼:总收入大增63.2%,商业化强势增长

格隆汇
27 Mar

格隆汇3月27日丨乐普生物-B(02157.HK)发布公告,截至2024年12月31日止年度,报告期内,集团的总收入约为人民币3.678亿元,同比增长63.2%。2024年,集团录得销售普佑恒®(普特利单抗注射液)的收入约人民币3.003亿元,为2023年录得收入(约人民币1.014亿元)的三倍。就许可业务而言,集团已录得收入约人民币2200万元,其来自CMG901许可协议项下的里程碑付款及所提供...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10